Can clinical data predict progression to dementia in amnestic mild cognitive impairment?

Lesley Fellows1, Howard Bergman, Christina Wolfson

  • 1Dept. of Neurology and Neurosurgery, Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada.

Abstract

Insights

Elderly individuals with mild cognitive impairment (MCI) face a high risk of dementia. Older age at symptom onset was the sole clinical predictor identified in this study of MCI progression.

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Identifying predictors of dementia progression in MCI is crucial for early intervention.

Purpose of the Study:

  • To investigate if clinical history and physical examination findings can predict dementia development in elderly individuals with amnestic MCI.
  • To identify specific clinical parameters associated with progression from MCI to dementia.

Main Methods:

  • Prospective, longitudinal study of 90 elderly subjects diagnosed with amnestic MCI.
  • Annual clinical assessments and neuropsychological evaluations over an average follow-up of 3.3 years.
  • Multivariate logistic regression analysis to identify predictors of dementia development.

Main Results:

  • 56% of participants progressed to dementia within the follow-up period.
  • Individuals who developed dementia were older, had lower Mini-Mental State Examination (MMSE) scores, and shorter symptom duration at baseline.
  • Older age at symptom onset was the only statistically significant clinical predictor (OR=1.1, CI 1.04-1.18).

Conclusions:

  • Amnestic MCI significantly increases the risk of dementia development.
  • Older age at symptom onset is a key clinical predictor for dementia progression in MCI patients.
  • Clinical features alone are insufficient for precise prediction of dementia development in MCI.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...